CALT Calliditas Therapeutics AB ADRs

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Lead product candidate Nefecon is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, (IgAN) for which there is a high unmet medical need and there are no approved treatments. This is an ADR of a company whose stock trades outside of the U.S. as the symbol SS:CALTX.

$28.48  -0.36 (-1.25%)
As of 02/26/2021 15:54:08 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
ADRs
Micro cap
Health Care
Drug Manufacturers—Specialty &
Sweden

06/05/2020
400,000
48,159
$11,536,000
0.00%
SEC Edgar Online
20-F



Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
0.01
13.20
-35.81%
-49,598.86%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy